Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients

Peritoneal Dialysis International

Volumn 19, Issue 3, 1999, Pages 280-283

  Lee, Mee Sook ^a   Kim, Soon Mi ^b   Kim, Soon Bae ^a   Lee, Sang Koo ^a   Park, Jung Sik ^a   Yang, Won Seok ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GEMFIBROZIL; LIPID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033375035     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901900319     Document Type: Article

References (14)

1. Meade TW. Thrombosis and ischemic heart disease. Br Heart J 1985; 53:473-6.
2. Skartlien AH, Lyberg-Beckmann S, Holme I, Hjermann I, Prydz H. Effect of alteration in triglyceride levels on factor VII-phospholipid complexes in plasma. Arteriosclerosis 1989; 9:798-801.
3. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34:457-62.
4. Athyros VG, Papageorgiou AA, Avramidis MJ, Kontopoulos AG. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia. Coron Artery Dis 1995; 6:251-6.
5. Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 1990; 63:174-7.
6. Irish AB, Thompson CH. The effects of gemfibrozil upon the hypercoagulable state in dyslipidemic patients with chronic renal failure. Nephrol Dial Transplant 1996; 11:2223-8.
7. Akcicek F, Ok E, Duman S, Kursad S, Unsal A, Alev M, et al. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: A prospective cross-over study. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1996; 12:261-5.
8. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, et al. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: A controlled study in human chronic renal disease. Nephron 1997; 75:286-94.
9. Browner WS, Black D, Newman TB, Hulley SB. Estimating sample size and power. In: Hulley SB, Cumming SR, eds. Designing clinical research. Baltimore: Williams & Wilkins, 1988; Chap 13:139-50.
10. Kim SB, Yang WS, Lee SK, Chi HS, Park JS. Effect of increasing serum albumin on haemostatic factors synthesized in the liver in CAPD patients. Nephrol Dial Transplant 1998; 13:2053-8.
11. Blann AD, Jackson P, Bath PM, Watts GF. Von Willebrand factor, a possible indicator of endothelial cell damage, decreases during long-term compliance with a lipid-lowering diet. J Intern Med 1995; 237: 557-61.
12. Elisaf MS, Dardamanis MA, Papagalanis ND, Siamopoulos KC. Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. Scand J Urol Nephrol 1993; 27:101-8.
13. Gault MH, Longerich LL, Purchase L, Harnett J, Breckenridge C. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 1995; 70:155-70.
14. Schlechte JA, Kreisberg R. Update in endocrinology. Ann Intern Med 1998; 129:719-25.